# A comparative analysis of three pharmacovigilance system assessment tools

## TL;DR

This paper compares three tools used to assess national drug safety systems, highlighting their strengths and limitations for better evaluation.

## Contribution

The study provides a comparative analysis of three pharmacovigilance tools to guide their effective use in diverse contexts.

## Key findings

- The tools cover different dimensions like infrastructure and outcomes but may miss critical components if used alone.
- A tailored or integrated approach is recommended for comprehensive evaluations of drug safety systems.
- Context-specific adaptation is emphasized to improve the accuracy of assessments.

## Abstract

Three key tools are currently available for assessing pharmacovigilance systems at the national level: the Indicator-Based Pharmacovigilance Assessment Tool (IPAT), the World Health Organization (WHO) Pharmacovigilance Indicators, and the Vigilance Module of the WHO Global Benchmarking Tool (GBT). These instruments are designed to evaluate the functionality and performance of national regulatory authorities within the context of their respective pharmacovigilance systems.

This study aims to identify, analyze, and compare the core characteristics and operational features of these pharmacovigilance assessment tools to better understand their scope, application, and limitations.

A structured document analysis was conducted on the three identified tools. The content was systematically reviewed, categorized, and synthesized to facilitate a comparative evaluation of its design, focus areas, and assessment criteria.

The analysis revealed that the available tools encompass a broad spectrum of indicators targeting different dimensions of pharmacovigilance systems, such as infrastructure, processes, and outcomes. However, exclusive reliance on a single tool may offer a limited perspective, potentially overlooking critical components of a national pharmacovigilance framework.

This study underscores the heterogeneity of existing pharmacovigilance assessment tools and emphasizes the importance of context-specific adaptation. A tailored approach, involving the strategic selection or integration of tools, is recommended to ensure a comprehensive and accurate evaluation of national pharmacovigilance systems.